(secondQuint)Perillyl Alcohol in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy.

 OBJECTIVES: I.

 Evaluate the clinical effectiveness of oral perillyl alcohol given to patients with androgen independent metastatic prostate cancer.

 II.

 Assess the toxicity of this treatment in these patients.

 OUTLINE: Patients receive oral perillyl alcohol 4 times a day for 4 weeks.

 Patients continue treatment in the absence of severe toxicity and disease progression.

 Patients are followed every 3 months for survival after disease progression.

 PROJECTED ACCRUAL: This study will accrue 20-40 patients in approximately 2 years.

.

 Perillyl Alcohol in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy@highlight

RATIONALE: Drugs used in chemotherapy use different way to stop tumor cells from dividing so they stop growing or die.

 PURPOSE: Phase II trial to study the effectiveness of perillyl alcohol in treating patients with metastatic prostate cancer that has not responded to hormone therapy with androgens.

